Newswise — Bethesda, Md.—The American Physiological Society is proud to host the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics September 2–5 in Savannah, Ga. The meeting will convene leading global researchers who study endothelin—a type of powerful peptide that constricts blood vessels, raises blood pressure and controls many other cellular functions throughout the body. When endothelin peptides are overexpressed, they can contribute to high blood pressure, cardiovascular disease and other vascular and non-vascular health problems such as diabetes, sickle cell anemia and kidney disease.
“A fascinating aspect of this meeting is that it includes a strong representation from the pharmaceutical industry including individuals who have been pioneers in developing new drugs for the treatment of diverse disorders such as pulmonary hypertension, diabetic nephropathy, cancer and others,” said David Pollock, PhD, one of the conference organizers. “The bulk of the meeting is based on submitted abstracts so much of the latest research in endothelin will be presented. This year’s meeting also includes a session devoted specifically to the development of new state-of-the-art therapies.”
Program Highlights
Friday, September 4, 2015Symposia I: Endothelin Synthesis and Receptor BehaviorKeynote Speaker: Janet Maguire, University of Cambridge, UK“New Insights in ET Receptor Pharmacology”
Symposia II: The Immune System and EndothelinKeynote Speaker: David Harrison, Vanderbilt University School of Medicine“Inflammation, Immunity and Hypertension”
Symposia III: ET, Sex and PregnancyKeynote Speaker: Jennifer Sullivan, Georgia Regents University“Sex and Hypertension”
Symposia IV: Roles of ET-1 on Vascular Function and DiseasesKeynote Speaker: Noriaki Emoto, Kobe University Graduate School of Medicine, Kyoto, Japan“ET-1 in the Heart in Health Disease”
Symposia V: Endothelin and Diabetes and MetabolismKeynote Speaker: John Pernow, Karolinska Institutet, Stockholm, Sweden“Endothelin and Diabetic Complications”
Symposia VI: Endothelin-1 and AngiogenesisKeynote Speaker: Anton H. van den Meiracker, Erasmus University Medical Center, Rotterdam, the Netherlands“ET and Anti-angiogenic Therapy”
Symposia VII: ET-1 in the KidneyKeynote Speaker: Neeraj Dhaun, University of Edinburgh, UK“ET Therapy in Kidney Disease”
Symposia VIII: Exercise and Pulmonary Function
Saturday, September 5, 2015Symposia IX: Central Nervous System and PainKeynote Speaker: Wolfgang Liedtke, Duke University Medical Center“Mechanisms of ET in Pain”
Symposia X: Neurovascular CouplingKeynote Speaker: Constantino Iadecola, Weill Cornell Medical College“ET and Neurovascular Coupling”
Symposia XI: Endothelin Therapeutics—Where Are We?Speakers:Anna Bagnato, Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri, Rome, Italy“Endothelin Therapeutics in Cancer—Where Are We?”
Donald Kohan, University of Utah Health Sciences Center“Endothelin Antagonists in Diabetic Nephropathy”
Pierre-Louis Tharaux, French Institute of Health and Medical Research (INSERM), Paris, France“Endothelin Receptor Antagonism in Sickle Cell Nephropathy”
Radko Komers, Retrophin Inc.“Combined AT1 and ETA Blockade”
Martine Clozel, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland“Endothelin Research and Drug Recovery”
NOTE TO EDITORS: The 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics (#Endothelin14) will be held September 2–5 in Savannah, Ga. The press is invited to attend. Please contact APS Communications for additional information.
Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 11,000 members and publishes 14 peer-reviewed journals with a worldwide readership.
RSS